151 related articles for article (PubMed ID: 28835078)
1. [Killing effect of icotinib combined with CIK on human lung adenocarcinoma cells in vitro].
Yao BQ; Jia Y; Guo JQ; Zhao Q; Sun H; Zhang JP
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):573-578. PubMed ID: 28835078
[No Abstract] [Full Text] [Related]
2. [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Zhou Y; Zhang S; Li K; Li QW; Zhou FZ; Li ZY; Ma H; Dong XR; Liu L; Wu G; Meng R
Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):100-4. PubMed ID: 26899328
[TBL] [Abstract][Full Text] [Related]
3. [Effects of icotinib hydrochloride on the proliferation and apoptosis of human lung cancer cell lines].
Ma L; Han XH; Wang S; Wang JF; Shi YK
Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(36):2561-4. PubMed ID: 23158799
[TBL] [Abstract][Full Text] [Related]
4. Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo.
Liu T; Jin L; Lu W; Gan H; Lin Z; Chen M; Liu J; Zhang F; Wang S; Zhang H; Deng W; Chen H
J Exp Clin Cancer Res; 2019 Apr; 38(1):148. PubMed ID: 30953548
[TBL] [Abstract][Full Text] [Related]
5. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.
Cui J; Zhang Y; Su D; Li T; Li Y
Thorac Cancer; 2018 Sep; 9(9):1156-1165. PubMed ID: 30047610
[TBL] [Abstract][Full Text] [Related]
7. Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
Li K; Zhou F; Zhou Y; Zhang S; Li Q; Li Z; Liu L; Wu G; Meng R
Int J Mol Med; 2019 Aug; 44(2):437-446. PubMed ID: 31173177
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y
Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936
[TBL] [Abstract][Full Text] [Related]
9. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.
Xu L; Qi Q; Zhang Y; Cui J; Liu R; Li Y
Lung Cancer; 2019 Jul; 133():23-31. PubMed ID: 31200823
[TBL] [Abstract][Full Text] [Related]
10. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
11. Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells.
Wang GH; Hu ZY
Math Biosci Eng; 2019 Aug; 16(6):7707-7718. PubMed ID: 31698635
[No Abstract] [Full Text] [Related]
12. Erlotinib enhances the CIK cell-killing sensitivity of lung adenocarcinoma A549 cells.
Mei JZ; Liu GJ; Zhang XJ; Zhao JZ; Feng RT
Genet Mol Res; 2015 Apr; 14(2):3082-9. PubMed ID: 25966072
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Zhao X; Zhu G; Chen H; Yang P; Li F; Du N
J Cancer Res Ther; 2014 Nov; 10 Suppl():C155-9. PubMed ID: 25450275
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Zhao X; Zhu G; Chen H; Yang P; Li F; Du N
J Cancer Res Ther; 2016; 12(3):1127-1131. PubMed ID: 28054523
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y
Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056
[TBL] [Abstract][Full Text] [Related]
16. [Proliferation and cytotoxicity of RetroNectin-activated cytokine-induced killer cells against cisplatin-resistant lung carcinoma cell].
Ren W; Wang Z
Sheng Wu Gong Cheng Xue Bao; 2008 Aug; 24(8):1373-80. PubMed ID: 18998538
[TBL] [Abstract][Full Text] [Related]
17. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
[TBL] [Abstract][Full Text] [Related]
18. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Yang G; Yao Y; Zhou J; Zhao Q
Oncol Rep; 2012 Jun; 27(6):2066-72. PubMed ID: 22446631
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo].
Yang XJ; Huang JA; Lei W; Zhu YB; Zhang XG
Ai Zheng; 2006 Nov; 25(11):1329-33. PubMed ID: 17094896
[TBL] [Abstract][Full Text] [Related]
20. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
Fan Y; Xu Y; Gong L; Fang L; Lu H; Qin J; Han N; Xie F; Qiu G; Huang Z
Sci Rep; 2017 Mar; 7():45193. PubMed ID: 28332624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
